June 22, 2015 Participation in PEGS Summit 2015
From 4th to 8th of May 2015 Rentschler attended the Eleventh Annual PEGS Summit in Boston, MA. This conference brought together leading experts for the discovery, development and manufacturing of new biotherapeutics. With a record attendance of approximate 2.000 participants from over 30 countries, attendees took advantage of the copious networking opportunities. In eight streams the participants have been informed about antibody engineering, protein expression and analysis and innovative biological candidates especially for oncology and immunotherapy. As new market trends, the development of toxic fusion proteins, antibody drug conjugates and cell therapies were discussed.
Rentschler was represented by Dr. Stefan Schmidt, Vice President Process Science and Production, who took over various functions: He was Chairman for the session “Strategies for engineering fusion protein therapeutics”, leading a workshop on the topic “Solving manufacturing issues of fusion proteins” and speaker.
His presentation under the heading “Therapeutic Fusion Proteins: Current Trends and Challenges” has been followed by more than 100 visitors. Dr. Schmidt provided an overview of the design and development of fusion proteins and described the key factors for commercial success of fusion protein candidates.
The fusion protein development pipeline continues to grow and the revenues of the approved products rise. However, there is also expected an increasing competition with alternative formats such as pegylated proteins and antibody drug conjugates.
Dr. Schmidt presented a variety of fusion components and mode of actions. In any case, the group of fusion proteins is an important element of modern biopharmaceutical treatments and leads to clear benefits for the patients.
Fusion proteins can be challenging to manufacture. Rarely platform processes exist. Rentschler as one of the leading biopharmaceutical CDMO’s has a broad expertise in the process development and manufacturing of fusions with and without Fc components. Using a modular approach optimal solutions for each fusion protein can be found.
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication